A Phase 3 interventional study of BNT162b2 and Placebo in SARS-CoV-2 Infection and COVID-19, sponsored by BioNTech SE. Completed at 26 sites in 2 countries. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-12.
Sponsored by BioNTech SE · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.
Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 11th largest by enrollment, is one of 8 that started in 2022, is one of 18 in phase 3, and was the 40th registered.
7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Technical University of Munich · Sites in Austria, Belgium, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
PharmaJet, Inc. · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 23 · Phase 4 11
First in 2020; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,134 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 575 across the 54 interventional studies. Of the 39 that completed or were terminated, 28 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
35 studies in COVID-19 by BioNTech SE: 2 open now, 2 under way, 1 of them phase 3. Of 31 finished, 25 (81%) have results posted.
Among the 35 studies in COVID-19 by BioNTech SE, this one is the 14th largest by enrollment, is one of 5 that started in 2022, is one of 14 in phase 3, and was the 21st registered.
BioNTech SE’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing BNT162 Vaccine in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing BNT162 Vaccine in COVID-19, from their registry updates:
Among BioNTech SE’s 35 in COVID-19:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and immunogenicity of a fourth dose (booster) of BNT162b2 when coadministered with SIIV compared to separate administration of the vaccines when given 1 month apart (SIIV followed by BNT162b2), in participants who have received 3 prior doses of 30 µg BNT162b2, with the third dose being at least 90 days before Visit 1 (Day 1).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BNT162b2 and SIIV followed by placebo a month later
Biological: BNT162b2 · Other: Placebo · Biological: Seasonal Inactivated Influenza Vaccine
Placebo and SIIV followed by BNT162b2 a month later
Biological: BNT162b2 · Other: Placebo · Biological: Seasonal Inactivated Influenza Vaccine
Intramuscular injection
Saline intramuscular injection
SIIV intramuscular injection
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1
Local reactions included redness, swelling, and pain at the injection site occurring at the BNT162b2 or placebo injection site. Local reactions were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, and potentially life threatening (Grade 4): necrosis or exfoliative dermatitis. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity, and potentially life threatening (Grade 4): emergency room visit or hospitalization for severe pain. Exact 2-sided confidence interval (CI), based on the Clopper and Pearson method was used.
Time frame: Within 7 Days After Vaccination 1
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2
Local reactions included redness, swelling, and pain at the injection site occurring at the BNT162b2 or placebo injection site. Local reactions were recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: greater than \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, and potentially life threatening (Grade 4): necrosis or exfoliative dermatitis. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity, and potentially life threatening (Grade 4): emergency room visit or hospitalization for severe pain. Exact 2-sided CI, based on the Clopper and Pearson method was used.
Time frame: Within 7 Days After Vaccination 2
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain recorded by participants in an e-diary. Fever was defined as temperature: \>=38.0 degrees (deg) Celsius (C), and categorized as: \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C, and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity, and severe: prevented daily routine activity. Vomiting graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h, severe: required intravenous hydration, and grade 4: emergency room (ER) visit or hospitalization for hypotensive shock. Diarrhea graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h, severe: 6 or more loose stools in 24h, and grade 4: ER visit or hospitalization for severe diarrhea.
Time frame: Within 7 Days After Vaccination 1
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain recorded by participants in an e-diary. Fever was defined as temperature: \>=38.0 deg C, and categorized as: \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C, and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity, and severe: prevented daily routine activity. Vomiting graded as mild: 1 to 2 times in 24h, moderate: \>2 times in 24h, severe: required intravenous hydration, and grade 4: ER visit or hospitalization for hypotensive shock. Diarrhea graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h, severe: 6 or more loose stools in 24h, and grade 4: ER visit or hospitalization for severe diarrhea. Exact 2-sided CI, based on Clopper and Pearson method used.
Time frame: Within 7 Days After Vaccination 2
Percentage of Participants With Adverse Events Within 1 Month After Vaccination 1
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Within 1 month after Vaccination 1
Percentage of Participants With Adverse Events Within 1 Month After Vaccination 2
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Within 1 month after Vaccination 2
Percentage of Participants With Serious Adverse Events Within 1 Month After Vaccination 1
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; or that was considered to be an important medical event.
Time frame: Within 1 Month After Vaccination 1
Percentage of Participants With Serious Adverse Events Within 1 Month After Vaccination 2
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; or that was considered to be an important medical event.
Time frame: Within 1 Month After Vaccination 2
Geometric Mean Ratio (GMR) Based on Geometric Mean Concentration (GMC) of Full-Length S-binding Immunoglobulin G (IgG) at 1 Month After BNT162b2 Vaccination
GMCs of full-length S-binding IgG level for the coadministration group and separate administration group were reported in this outcome measure in descriptive data section. GMC and the 2-sided 95% CI were calculated by exponentiating the LSMeans of the concentrations and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of vaccine group, age group, and the corresponding baseline assay results (log scale). Assay results below the LLOQ were set to 0.5\*LLOQ. Geometric mean ratio (GMR) was reported in the statistical analysis section and was calculated as ratio of GMCs in the coadministration group to the separate administration group. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure.
Time frame: 1 Month After BNT162b2 vaccination
Geometric Mean Ratio (GMR) Based on Geometric Mean Titer (GMT) of Strain-Specific Hemagglutination Inhibition (HAI) at 1 Month After SIIV Vaccination
GMTs of strain-specific HAI titers for the coadministration group and separate administration group were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the LSMeans of the titers and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of vaccine group, age group, and the corresponding baseline assay results (log scale). Assay results below the LLOQ were set to 0.5\*LLOQ, and results above the ULOQ were set to ULOQ+1. Geometric mean ratio (GMR) was reported in the statistical analysis section and was calculated as ratio of GMT in the coadministration group to the separate administration group.
Time frame: 1 Month After SIIV vaccination
Geometric Mean Concentration (GMC) of Full-Length S-binding IgG Levels Before Vaccination and 1 Month After BNT162b2 Vaccination
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t-distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''.
Time frame: Before BNT162b2 vaccination, and 1 month After BNT162b2 vaccination
Geometric Mean Fold Rise (GMFR) of Full-Length S-binding IgG Levels From Before Vaccination to 1 Month After BNT162b2 Vaccination
GMFR was defined as the geometric mean of the ratios of IgG concentrations at 1 month after BNT162b2 vaccination to that before BNT162b2 vaccination. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''.
Time frame: From before BNT162b2 vaccination to 1 month After BNT162b2 vaccination
Geometric Mean Titer (GMT) of SARS-CoV-2 Neutralizing Titers Before Vaccination and 1 Month After BNT162b2 Vaccination
GMTs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student's t-distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''. Analysis was performed in a subset of 100 participants from each group.
Time frame: Before BNT162b2 vaccination, and 1 month after BNT162b2 vaccination
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After BNT162b2 Vaccination
GMFR was defined as the geometric mean of the ratios of SARS-CoV-2 neutralizing titers at 1 month after BNT162b2 vaccination to that before BNT162b2 vaccination. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''. Analysis was performed in a subset of 100 participants from each group.
Time frame: From before BNT162b2 vaccination to 1 month after BNT162b2 vaccination
Geometric Mean Titer (GMT) of Strain-Specific HAI Titers Before Vaccination and 1 Month After SIIV Vaccination
GMTs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ, and results above the ULOQ were set to ULOQ+1. The analysis was performed on the influenza strains: H1N1 A/Victoria, H3N2 A/Darwin, B/Austria, and B/Phuket.
Time frame: Before SIIV vaccination, and 1 month after SIIV vaccination
Geometric Mean Fold Rise (GMFR) of Strain-Specific HAI Titers From Before Vaccination to 1 Month After SIIV Vaccination
GMFR was defined as ratio of the geometric mean of strain-specific HAI titers at 1 month after SIIV vaccination to the geometric mean of strain-specific HAI titers before SIIV vaccination. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ, and results above the ULOQ were set to ULOQ+1. The analysis was performed on the influenza strains: H1N1 A/Victoria, H3N2 A/Darwin, B/Austria, and B/Phuket.
Time frame: From before vaccination to 1 month after SIIV vaccination
A total of 1165 participants were screened, out of which 31 were screen failures and 1134 were randomized into the study.
| Milestone | Coadministration Group | Separate Administration Group |
|---|---|---|
| Started | 568 | 566 |
| Vaccinated | 564 | 564 |
| Completed | 560 | 555 |
| Not completed | 8 | 11 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Participant availability | 0 | 4 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Randomized but not vaccinated | 4 | 2 |
Local reactions included redness, swelling, and pain at the injection site occurring at the BNT162b2 or placebo injection site. Local reactions were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, and potentially life threatening (Grade 4): necrosis or exfoliative dermatitis. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity, and potentially life threatening (Grade 4): emergency room visit or hospitalization for severe pain. Exact 2-sided confidence interval (CI), based on the Clopper and Pearson method was used.
| Percentage of participants | Coadministration Group | Separate Administration Group |
|---|---|---|
| Redness: Any | 7.6 (5.6 to 10.1) | 0.5 (0.1 to 1.6) |
| Redness: Mild | 6.2 (4.4 to 8.5) | 0.5 (0.1 to 1.6) |
| Redness: Moderate | 1.2 (0.5 to 2.5) | 0 (0.0 to 0.7) |
| Redness: Severe | 0.2 (0.0 to 1.0) | 0 (0.0 to 0.7) |
| Redness: Grade 4 | 0 (0.0 to 0.7) | 0 (0 to 0.7) |
| Swelling: Any | 9.2 (7.0 to 11.9) | 1.1 (0.4 to 2.3) |
| Swelling: Mild | 6.2 (4.4 to 8.5) | 0.4 (0.0 to 1.3) |
| Swelling: Moderate | 3.0 (1.8 to 4.8) | 0.7 (0.2 to 1.8) |
| Swelling: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Swelling: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Pain at the injection site: Any | 86.2 (83.0 to 88.9) | 13.9 (11.1 to 17.0) |
| Pain at the injection site: Mild | 66.3 (62.2 to 70.2) | 13.5 (10.8 to 16.6) |
| Pain at the injection site: Moderate | 19.9 (16.6 to 23.4) | 0.4 (0.0 to 1.3) |
| Pain at the injection site: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
Local reactions included redness, swelling, and pain at the injection site occurring at the BNT162b2 or placebo injection site. Local reactions were recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: greater than \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, and potentially life threatening (Grade 4): necrosis or exfoliative dermatitis. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity, and potentially life threatening (Grade 4): emergency room visit or hospitalization for severe pain. Exact 2-sided CI, based on the Clopper and Pearson method was used.
| Percentage of participants | Coadministration Group | Separate Administration Group |
|---|---|---|
| Redness: Any | 0.2 (0.0 to 1.0) | 4.7 (3.1 to 6.8) |
| Redness: Mild | 0.2 (0.0 to 1.0) | 4.3 (2.8 to 6.4) |
| Redness: Moderate | 0 (0.0 to 0.7) | 0.4 (0.0 to 1.3) |
| Redness: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Redness: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Swelling: Any | 0.4 (0.0 to 1.3) | 8.9 (6.6 to 11.5) |
| Swelling: Mild | 0.4 (0.0 to 1.3) | 5.8 (4.0 to 8.1) |
| Swelling: Moderate | 0 (0.0 to 0.7) | 3.1 (1.8 to 4.9) |
| Swelling: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Swelling: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Pain at the injection site: Any | 6.6 (4.7 to 9.0) | 84.4 (81.2 to 87.4) |
| Pain at the injection site: Mild | 6.3 (4.4 to 8.6) | 61.7 (57.5 to 65.7) |
| Pain at the injection site: Moderate | 0.4 (0.0 to 1.3) | 22.4 (19.0 to 26.1) |
| Pain at the injection site: Severe | 0 (0.0 to 0.7) | 0.4 (0.0 to 1.3) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain recorded by participants in an e-diary. Fever was defined as temperature: \>=38.0 degrees (deg) Celsius (C), and categorized as: \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C, and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity, and severe: prevented daily routine activity. Vomiting graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h, severe: required intravenous hydration, and grade 4: emergency room (ER) visit or hospitalization for hypotensive shock. Diarrhea graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h, severe: 6 or more loose stools in 24h, and grade 4: ER visit or hospitalization for severe diarrhea.
| Percentage of participants | Coadministration Group | Separate Administration Group |
|---|---|---|
| Fever: >=38.0 deg C | 2.0 (1.0 to 3.5) | 1.1 (0.4 to 2.3) |
| Fever: >=38.0 deg C to 38.4 deg C | 1.2 (0.5 to 2.5) | 0.4 (0.0 to 1.3) |
| Fever: >38.4 deg C to 38.9 deg C | 0.4 (0.0 to 1.3) | 0.4 (0.0 to 1.3) |
| Fever: >38.9 deg C to 40.0 deg C | 0.4 (0.0 to 1.3) | 0.4 (0.0 to 1.3) |
| Fever: >40.0 deg C | 0.0 (0.0 to 0.7) | 0.0 (0.0 to 0.7) |
| Fatigue: Any | 64.0 (59.9 to 68.0) | 42.1 (38.0 to 46.3) |
| Fatigue: Mild | 31.9 (28.1 to 35.9) | 24.7 (21.2 to 28.5) |
| Fatigue: Moderate | 30.9 (27.1 to 34.8) | 16.3 (13.4 to 19.7) |
| Fatigue: Severe | 1.2 (0.5 to 2.5) | 1.1 (0.4 to 2.3) |
| Fatigue: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Headache: Any | 47.2 (43.0 to 51.4) | 34.3 (30.4 to 38.4) |
| Headache: Mild | 28.2 (24.5 to 32.1) | 23.3 (19.9 to 27.0) |
| Headache: Moderate | 17.9 (14.8 to 21.3) | 10.3 (7.9 to 13.1) |
| Headache: Severe | 1.1 (0.4 to 2.3) | 0.7 (0.2 to 1.8) |
| Headache: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Chills: Any | 19.9 (16.6 to 23.4) | 6.2 (4.4 to 8.6) |
| Chills: Mild | 12.9 (10.3 to 16.0) | 4.3 (2.8 to 6.3) |
| Chills: Moderate | 6.0 (4.2 to 8.3) | 1.6 (0.7 to 3.0) |
| Chills: Severe | 0.9 (0.3 to 2.1) | 0.4 (0.0 to 1.3) |
| Chills: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Vomiting: Any | 2.7 (1.5 to 4.3) | 0.9 (0.3 to 2.1) |
| Vomiting: Mild | 2.3 (1.2 to 3.9) | 0.7 (0.2 to 1.8) |
| Vomiting: Moderate | 0.4 (0.0 to 1.3) | 0.2 (0.0 to 1.0) |
| Vomiting: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Vomiting: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Diarrhea: Any | 11.5 (9.0 to 14.5) | 10.1 (7.8 to 12.9) |
| Diarrhea: Mild | 9.9 (7.6 to 12.7) | 8.9 (6.7 to 11.6) |
| Diarrhea: Moderate | 1.4 (0.6 to 2.8) | 1.2 (0.5 to 2.5) |
| Diarrhea: Severe | 0.2 (0.0 to 1.0) | 0 (0.0 to 0.7) |
| Diarrhea: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| New or worsened muscle pain: Any | 27.7 (24.0 to 31.6) | 11.4 (8.9 to 14.3) |
| New or worsened muscle pain: Mild | 15.8 (12.9 to 19.1) | 6.2 (4.4 to 8.6) |
| New or worsened muscle pain: Moderate | 11.3 (8.8 to 14.3) | 5.0 (3.3 to 7.1) |
| New or worsened muscle pain: Severe | 0.5 (0.1 to 1.5) | 0.2 (0.0 to 1.0) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| New or worsened joint pain: Any | 15.1 (12.2 to 18.3) | 5.3 (3.6 to 7.5) |
| New or worsened joint pain: Mild | 10.3 (7.9 to 13.1) | 2.7 (1.5 to 4.4) |
| New or worsened joint pain: Moderate | 4.8 (3.2 to 6.9) | 2.7 (1.5 to 4.4) |
| New or worsened joint pain: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain recorded by participants in an e-diary. Fever was defined as temperature: \>=38.0 deg C, and categorized as: \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C, and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity, and severe: prevented daily routine activity. Vomiting graded as mild: 1 to 2 times in 24h, moderate: \>2 times in 24h, severe: required intravenous hydration, and grade 4: ER visit or hospitalization for hypotensive shock. Diarrhea graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h, severe: 6 or more loose stools in 24h, and grade 4: ER visit or hospitalization for severe diarrhea. Exact 2-sided CI, based on Clopper and Pearson method used.
| Percentage of participants | Coadministration Group | Separate Administration Group |
|---|---|---|
| Fever: >=38.0 deg C | 1.1 (0.4 to 2.3) | 1.6 (0.7 to 3.1) |
| Fever: >=38.0 deg C to 38.4 deg C | 0.5 (0.1 to 1.6) | 1.1 (0.4 to 2.3) |
| Fever: >38.4 deg C to 38.9 deg C | 0.5 (0.1 to 1.6) | 0.5 (0.1 to 1.6) |
| Fever: >38.9 deg C to 40.0 deg C | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Fever: >40.0 deg C | 0. (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Fatigue: Any | 21.7 (18.4 to 25.4) | 50.8 (46.6 to 55.1) |
| Fatigue: Mild | 12.4 (9.8 to 15.4) | 27.3 (23.6 to 31.2) |
| Fatigue: Moderate | 8.6 (6.4 to 11.3) | 22.1 (18.7 to 25.8) |
| Fatigue: Severe | 0.7 (0.2 to 1.8) | 1.4 (0.6 to 2.8) |
| Fatigue: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Headache: Any | 20.8 (17.5 to 24.4) | 37.8 (33.7 to 42.0) |
| Headache: Mild | 13.1 (10.4 to 16.2) | 25.0 (21.4 to 28.8) |
| Headache: Moderate | 7.5 (5.5 to 10.1) | 12.1 (9.5 to 15.1) |
| Headache: Severe | 0.2 (0.0 to 1.0) | 0.7 (0.2 to 1.8) |
| Headache: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Chills: Any | 3.4 (2.1 to 5.3) | 13.4 (10.7 to 16.5) |
| Chills: Mild | 2.3 (1.2 to 4.0) | 8.5 (6.3 to 11.1) |
| Chills: Moderate | 1.1 (0.4 to 2.3) | 4.7 (3.1 to 6.8) |
| Chills: Severe | 0 (0.0 to 0.7) | 0.2 (0.0 to 1.0) |
| Chills: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Vomiting: Any | 1.1 (0.4 to 2.3) | 2.4 (1.3 to 4.0) |
| Vomiting: Mild | 0.7 (0.2 to 1.8) | 1.8 (0.9 to 3.3) |
| Vomiting: Moderate | 0.4 (0.0 to 1.3) | 0.5 (0.1 to 1.6) |
| Vomiting: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Vomiting: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| Diarrhea: Any | 4.5 (2.9 to 6.6) | 6.5 (4.6 to 8.9) |
| Diarrhea: Mild | 3.8 (2.3 to 5.7) | 5.2 (3.5 to 7.4) |
| Diarrhea: Moderate | 0.7 (0.2 to 1.8) | 0.9 (0.3 to 2.1) |
| Diarrhea: Severe | 0 (0.0 to 0.7) | 0.4 (0.0 to 1.3) |
| Diarrhea: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| New or worsened muscle pain: Any | 5.2 (3.5 to 7.4) | 23.5 (20.0 to 27.3) |
| New or worsened muscle pain: Mild | 2.7 (1.5 to 4.4) | 12.8 (10.2 to 15.9) |
| New or worsened muscle pain: Moderate | 2.5 (1.4 to 4.2) | 10.5 (8.1 to 13.3) |
| New or worsened muscle pain: Severe | 0 (0.0 to 0.7) | 0.2 (0.0 to 1.0) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| New or worsened joint pain: Any | 3.4 (2.1 to 5.3) | 9.8 (7.4 to 12.5) |
| New or worsened joint pain: Mild | 2.0 (1.0 to 3.5) | 5.6 (3.8 to 7.9) |
| New or worsened joint pain: Moderate | 1.4 (0.6 to 2.8) | 4.2 (2.7 to 6.2) |
| New or worsened joint pain: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 0.7) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Coadministration Group | Separate Administration Group |
|---|---|---|
| Percentage of Participants With Adverse Events Within 1 Month After Vaccination 1 | 31.6 (27.7 to 35.6) | 30.5 (26.7 to 34.5) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Coadministration Group | Separate Administration Group |
|---|---|---|
| Percentage of Participants With Adverse Events Within 1 Month After Vaccination 2 | 29.0 (25.3 to 32.9) | 25.1 (21.6 to 29.0) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; or that was considered to be an important medical event.
| Percentage of participants | Coadministration Group | Separate Administration Group |
|---|---|---|
| Percentage of Participants With Serious Adverse Events Within 1 Month After Vaccination 1 | 0.4 (0.0 to 1.3) | 0.2 (0.0 to 1.0) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; or that was considered to be an important medical event.
| Percentage of participants | Coadministration Group | Separate Administration Group |
|---|---|---|
| Percentage of Participants With Serious Adverse Events Within 1 Month After Vaccination 2 | 0.5 (0.1 to 1.6) | 0.7 (0.2 to 1.8) |
GMCs of full-length S-binding IgG level for the coadministration group and separate administration group were reported in this outcome measure in descriptive data section. GMC and the 2-sided 95% CI were calculated by exponentiating the LSMeans of the concentrations and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of vaccine group, age group, and the corresponding baseline assay results (log scale). Assay results below the LLOQ were set to 0.5\*LLOQ. Geometric mean ratio (GMR) was reported in the statistical analysis section and was calculated as ratio of GMCs in the coadministration group to the separate administration group. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure.
| Units per millilitre (U/mL) | Coadministration Group | Separate Administration Group |
|---|---|---|
| Geometric Mean Ratio (GMR) Based on Geometric Mean Concentration (GMC) of Full-Length S-binding Immunoglobulin G (IgG) at 1 Month After BNT162b2 Vaccination | 13767.8 (13110.0 to 14458.6) | 16644.5 (15774.7 to 17562.3) |
GMTs of strain-specific HAI titers for the coadministration group and separate administration group were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the LSMeans of the titers and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of vaccine group, age group, and the corresponding baseline assay results (log scale). Assay results below the LLOQ were set to 0.5\*LLOQ, and results above the ULOQ were set to ULOQ+1. Geometric mean ratio (GMR) was reported in the statistical analysis section and was calculated as ratio of GMT in the coadministration group to the separate administration group.
| Titer | Coadministration Group | Separate Administration Group |
|---|---|---|
| B/Austria | 80.1 (71.7 to 89.6) | 89.7 (80.0 to 100.7) |
| B/Phuket | 81.3 (74.4 to 88.9) | 81.3 (74.2 to 89.2) |
| H1N1 A/Victoria | 301.7 (273.1 to 333.4) | 316.5 (285.5 to 350.9) |
| H3N2 A/Darwin | 226.8 (207.2 to 248.3) | 235.6 (214.6 to 258.7) |
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t-distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''.
| Units per millilitre (U/mL) | Coadministration Group | Separate Administration Group |
|---|---|---|
| Before BNT162b2 Vaccination | 5520.3 (5034.7 to 6052.8) | 5272.3 (4704.3 to 5909.0) |
| 1 Month After BNT162b2 Vaccination | 13806.5 (12838.9 to 14847.0) | 16254.6 (15035.5 to 17572.5) |
GMFR was defined as the geometric mean of the ratios of IgG concentrations at 1 month after BNT162b2 vaccination to that before BNT162b2 vaccination. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''.
| Fold rise | Coadministration Group | Separate Administration Group |
|---|---|---|
| Geometric Mean Fold Rise (GMFR) of Full-Length S-binding IgG Levels From Before Vaccination to 1 Month After BNT162b2 Vaccination | 2.5 (2.4 to 2.7) | 3.1 (2.9 to 3.3) |
GMTs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student's t-distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''. Analysis was performed in a subset of 100 participants from each group.
| Titer | Coadministration Group | Separate Administration Group |
|---|---|---|
| Before BNT162b2 Vaccination | 2755.9 (2107.6 to 3603.4) | 2421.2 (1780.1 to 3293.3) |
| 1 Month After BNT162b2 Vaccination | 6773.9 (5545.0 to 8275.3) | 7886.6 (6264.9 to 9928.2) |
GMFR was defined as the geometric mean of the ratios of SARS-CoV-2 neutralizing titers at 1 month after BNT162b2 vaccination to that before BNT162b2 vaccination. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''. Analysis was performed in a subset of 100 participants from each group.
| Fold rise | Coadministration Group | Separate Administration Group |
|---|---|---|
| Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After BNT162b2 Vaccination | 2.5 (2.1 to 2.9) | 3.3 (2.7 to 3.9) |
GMTs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ, and results above the ULOQ were set to ULOQ+1. The analysis was performed on the influenza strains: H1N1 A/Victoria, H3N2 A/Darwin, B/Austria, and B/Phuket.
| Titer | Coadministration Group | Separate Administration Group |
|---|---|---|
| B/Austria: Before Vaccination | 13.0 (11.7 to 14.5) | 12.7 (11.5 to 14.1) |
| B/Austria: 1 Month After SIIV Vaccination | 72.4 (64.2 to 81.7) | 78.3 (69.3 to 88.5) |
| B/Phuket: Before Vaccination | 26.4 (23.8 to 29.4) | 25.7 (23.0 to 28.6) |
| B/Phuket: 1 Month After SIIV Vaccination | 87.4 (79.7 to 95.7) | 86.3 (78.4 to 94.9) |
| H1N1 A/Victoria: Before Vaccination | 57.0 (49.5 to 65.6) | 56.3 (48.9 to 64.7) |
| H1N1 A/Victoria: 1 Month After SIIV Vaccination | 344.3 (312.4 to 379.3) | 362.3 (326.8 to 401.6) |
| H3N2 A/Darwin: Before Vaccination | 39.5 (35.6 to 43.7) | 38.4 (34.5 to 42.8) |
| H3N2 A/Darwin: 1 Month After SIIV Vaccination | 230.6 (209.5 to 253.8) | 242.2 (221.2 to 265.2) |
GMFR was defined as ratio of the geometric mean of strain-specific HAI titers at 1 month after SIIV vaccination to the geometric mean of strain-specific HAI titers before SIIV vaccination. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ, and results above the ULOQ were set to ULOQ+1. The analysis was performed on the influenza strains: H1N1 A/Victoria, H3N2 A/Darwin, B/Austria, and B/Phuket.
| Fold rise | Coadministration Group | Separate Administration Group |
|---|---|---|
| B/Austria | 5.5 (4.9 to 6.2) | 6.3 (5.6 to 7.1) |
| B/Phuket | 3.3 (2.9 to 3.7) | 3.4 (3.0 to 3.8) |
| H1N1 A/Victoria | 6.0 (5.1 to 7.0) | 6.4 (5.5 to 7.5) |
| H3N2 A/Darwin | 5.9 (5.3 to 6.6) | 6.3 (5.6 to 7.1) |
Collected over AEs and SAEs: From Day 1 (Visit 1) to 1 month after last dose of study vaccine (approximately 2 months after Visit 1 [Day1]); Local reactions (at the BNT162b2/placebo injection site) and systemic events: Within 7 days after each vaccination. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Coadministration Group (Visit 1) | 0/564 (0%) | 2/564 (0.4%) | 532/564 (94.3%) |
| Coadministration Group (Visit 2) | 0/562 (0%) | 3/562 (0.5%) | 261/562 (46.4%) |
| Separate Administration Group (Visit 1) | 0/564 (0%) | 1/564 (0.2%) | 364/564 (64.5%) |
| Separate Administration Group (Visit 2) | 0/557 (0%) | 4/557 (0.7%) | 502/557 (90.1%) |
| Event | Coadministration Group (Visit 1) | Coadministration Group (Visit 2) | Separate Administration Group (Visit 1) | Separate Administration Group (Visit 2) |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/564 | 0/562 | 0/564 | 1/557 |
| ConcussionInjury, poisoning and procedural complications | 0/564 | 0/562 | 0/564 | 1/557 |
| Ligament sprainInjury, poisoning and procedural complications | 0/564 | 0/562 | 0/564 | 1/557 |
| PneumocephalusInjury, poisoning and procedural complications | 0/564 | 0/562 | 0/564 | 1/557 |
| Skull fractureInjury, poisoning and procedural complications | 0/564 | 0/562 | 0/564 | 1/557 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/564 | 0/562 | 0/564 | 1/557 |
| Intestinal perforationGastrointestinal disorders | 0/564 | 1/562 | 0/564 | 0/557 |
| CostochondritisMusculoskeletal and connective tissue disorders | 0/564 | 1/562 | 0/564 | 0/557 |
| Malignant melanoma stage IINeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/564 | 1/562 | 0/564 | 0/557 |
| Abscess limbInfections and infestations | 0/564 | 0/562 | 1/564 | 0/557 |
| Event | Coadministration Group (Visit 1) | Coadministration Group (Visit 2) | Separate Administration Group (Visit 1) | Separate Administration Group (Visit 2) |
|---|---|---|---|---|
| Injection site painGeneral disorders | 486/564 | 37/562 | 78/564 | 467/557 |
| FatigueGeneral disorders | 361/564 | 121/562 | 237/564 | 281/557 |
| HeadacheNervous system disorders | 266/564 | 116/562 | 193/564 | 209/557 |
| ChillsGeneral disorders | 112/564 | 19/562 | 35/564 | 74/557 |
| DiarrhoeaGastrointestinal disorders | 65/564 | 25/562 | 57/564 | 36/557 |
| COVID-19Infections and infestations | 46/564 | 63/562 | 56/564 | 48/557 |
| Injection site swellingGeneral disorders | 52/564 | 2/562 | 6/564 | 49/557 |
| Injection site erythemaGeneral disorders | 43/564 | 1/562 | 3/564 | 26/557 |
| Upper respiratory tract infectionInfections and infestations | 27/564 | 31/562 | 24/564 | 22/557 |
| Injection site painGeneral disorders | 16/564 | 1/562 | 14/564 | 1/557 |
Safety population included all participants who received any of the study intervention.
| Age, Continuous(Years) | Coadministration Group | Separate Administration Group | Total |
|---|---|---|---|
| Mean | 39.7 ± 13.20 | 39.8 ± 13.52 | 39.7 ± 13.35 |
| Sex: Female, Male(Participants) | Coadministration Group | Separate Administration Group | Total |
|---|---|---|---|
| Female | 356 | 361 | 717 |
| Male | 208 | 203 | 411 |
| Ethnicity (NIH/OMB)(Participants) | Coadministration Group | Separate Administration Group | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 9 | 14 |
| Not Hispanic or Latino | 539 | 537 | 1076 |
| Unknown or Not Reported | 20 | 18 | 38 |
| Race (NIH/OMB)(Participants) | Coadministration Group | Separate Administration Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 73 | 66 | 139 |
| Native Hawaiian or Other Pacific Islander | 26 | 36 | 62 |
| Black or African American | 1 | 2 | 3 |
| White | 446 | 439 | 885 |
| More than one race | 1 | 10 | 11 |
| Unknown or Not Reported | 17 | 11 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2022 to primary completion in Oct 2022, 5 months.
Results were first posted in Nov 2023, 1 year 1 month after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 5 months is below that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine